KODIAK SCIENCES INC. Shareholders' Equity
KODIAK SCIENCES INC. (KOD) had Shareholders' Equity of $61.10 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $61.10M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $112.10M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $157.38M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $23.69M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $61.10M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $112.10M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $157.38M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $23.69M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $70.29M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $108.84M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $150.29M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $185.37M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $214.51M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $241.19M 10-Q · filed 2025-11-13 |
| 2023-12-31 | $265.78M 10-K · filed 2026-03-31 |
| 2023-09-30 | $302.42M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $338.48M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $392.59M 10-Q · filed 2024-11-14 |
| 2022-12-31 | $436.17M 10-K · filed 2026-03-31 |
| 2022-09-30 | $479.53M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $530.93M 10-Q · filed 2023-11-14 |
| 2022-03-31 | $597.38M 10-Q · filed 2023-11-14 |
| 2021-12-31 | $663.32M 10-K · filed 2025-03-27 |
| 2021-09-30 | $726.32M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $779.43M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $821.68M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $860.75M 10-K · filed 2024-03-28 |
| 2020-09-30 | $281.78M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $309.20M 10-Q · filed 2021-11-09 |
| 2020-03-31 | $327.69M 10-Q · filed 2021-11-09 |
| 2019-12-31 | $345.36M 10-K · filed 2023-03-28 |
| 2019-09-30 | $59.69M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $70.02M 10-Q · filed 2020-11-09 |
| 2019-03-31 | $80.09M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $86.83M 10-K · filed 2022-03-01 |
| 2018-09-30 | -$93.83M 10-Q · filed 2019-11-12 |
| 2018-06-30 | -$84.23M 10-Q · filed 2019-11-12 |
| 2018-03-31 | -$77.57M 10-Q · filed 2019-11-12 |
| 2017-12-31 | -$68.74M 10-K · filed 2021-03-01 |
| 2016-12-31 | -$41.08M 10-K · filed 2020-03-16 |
| 2015-12-31 | -$24.24M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |